A TYPICAL PATIENT WITH ATRIAL FIBRILLATION AND RENAL DYSFUNCTION - HOW TO PREVENT STROKE?
Aim. To evaluate efficacy and safety of rivaroxaban for stroke and systemic embolism prevention in patients with AF of non-valvular cause and concomitant CKD. Material and methods. Totally 16 patients with AF included, having chronic kidney disease of II-III stages, who during a year were being assessed an efficacy - cases of death, stroke and systemic embolism, and drug safety (clinically significant and non-significant bleedings). Results. As a result for efficacy - stroke, systemic embolism, death cases were not registered. In assessment of safety, mild nasal bleedings (not needed medical help) were marked in 3 patients during one month of treatment, and in 2 patients there were non-persistent petechias. Clinically significant bleedings were not registered. Conclusion. The usage of the oral anticoagulant rivaroxaban in dose 20 mg and 15 mg per day in patients with AF of non-valvular cause with comorbid CKD II-III stage is effective and safe for the prevention of stroke and systemic embolism.